Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UHC Labels Checkpoint Inhibitors "Experimental" — and How to Break the Denial

When UnitedHealthcare denies Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, or Libtayo as experimental/investigational, the denial almost never reflects a true scientific judgment about PD-1/PD-L1 or CTLA-4 blockade as a class. Under the Oncology Medication Clinical Coverage – UHC Commercial Medical Benefit Drug Policy (eff. 04/01/2026), the experimental label is a downstream output of one of three mechanical filters: (1) the NCCN Compendium lists the indication as Category 3 (or does not list it at all), (2) the request is off-compendium/off-label without a recognized compendium citation, or (3) Optum's reviewer treats a biomarker mismatch (e.g., PD-L1 TPS <50% for first-line NSCLC monotherapy, MSS CRC without prior lines, low TMB) as lack of established efficacy. Decoding which filter triggered the denial is the entire battle.

Pull the denial letter and the OptumRx prior authorization worksheet — UHC routes checkpoint inhibitor PAs through Optum even though billing is medical-benefit (J-code, buy-and-bill or specialty pharmacy via Optum Specialty/BriovaRx). Under 29 CFR §2560.503-1(g), the adverse benefit determination must identify the specific clinical rationale and the policy provision relied upon. If the letter says "experimental" without naming the NCCN category or the missing biomarker, that is a per-se ERISA disclosure violation and grounds for remand.

If the indication is NCCN Category 2A or 2B, the policy itself deems it proven and medically necessary — cite the compendium entry with version number and panel-vote date directly in the appeal. If it is Category 3 or off-compendium, you must invoke an alternate compendium UHC recognizes implicitly via CMS-aligned standards (Micromedex DrugDex 1/2a/2b, AHFS, Lexi-Drugs) plus two peer-reviewed Phase II/III citations in MEDLINE-indexed journals. Pinto v. Aetna Life Insurance Co., 564 F. App'x 949 (10th Cir. 2014) controls the burden analysis: the plan must show the treatment is experimental, not the member show it is proven — and conclusory reviewer notes do not discharge that burden.

For self-funded ERISA plans, escalate to external review under 29 CFR §2590.715-2719 with an IRO; oncology IROs overturn checkpoint inhibitor experimental denials at rates above 60% when NCCN 2A/2B citations are presented. For fully insured plans, file simultaneously with the state DOI. If the patient is mid-cycle, demand continuity-of-care protections under 45 CFR §156.122(e) and an expedited 72-hour review under 29 CFR §2560.503-1(f)(2)(i).

Tactical tip: Request the reviewer's board certification and oncology subspecialty in writing — UHC must use a same-specialty peer reviewer for oncology adverse determinations, and a non-oncologist signing the denial is independent reversible error.